Seikagaku Corp. | Mutual Funds
Mutual Funds that own Seikagaku Corp.
CREF Stock Account
1,066,800
1.88%
-20,000
0.01%
03/31/2018
Invesco Funds - Japanese Equity Advantage Fd.
1,060,800
1.87%
-278,000
1.25%
03/29/2018
Nomura Asset TOPIX ETF Fund (1306)
612,700
1.08%
9,700
0.01%
07/31/2018
Government Pension Fund - Global (The)
585,199
1.03%
92,699
0%
12/31/2017
Vanguard Total International Stock Index Fund
529,378
0.93%
0
0%
07/31/2018
Daiwa Asset TOPIX Listed ETF (1305)
300,800
0.53%
5,400
0.01%
07/31/2018
Nikko Asset Listed Index TOPIX ETF (1308)
275,900
0.49%
0
0.01%
08/20/2018
iShares MSCI EAFE Small Cap ETF
236,700
0.42%
0
0.03%
09/06/2018
Vanguard Developed Markets Index Fund
205,900
0.36%
0
0%
07/31/2018
iShares Core MSCI EAFE ETF
149,400
0.26%
0
0%
09/06/2018
| Address |
Marunouchi Center Building, 10/F
Tokyo Tokyo 100
Japan
|
|
Employees
|
- |
| Website |
http://www.seikagaku.co.jp |
| Updated |
07/08/2019 |
| Seikagaku Corp. engages in the manufacture and sale of pharmaceuticals and medical devices specifically related to glycoconjugates. It operates through the following segments: Pharmaceuticals and Limulus Amebocyte Lysate (LAL). The Pharmaceuticals segment develops and supplies intra-articular injections for improving joint functions, cross-linked hyaluronate hydrogel for knee osteoarthritis, opthalmic surgical aids, and surgical aids for endoscopic mucosal resection. |
